keyword
MENU ▼
Read by QxMD icon Read
search

Aldosterone antagonist

keyword
https://www.readbyqxmd.com/read/29467196/specific-activation-of-the-alternative-cardiac-promoter-of-cacna1c-by-the-mineralocorticoid-receptor
#1
Thassio R Mesquita, Gaelle Auguste, Debora Falcón, Gema Ruiz-Hurtado, Rogelio Salazar-Enciso, Jessica Sabourin, Florence Lefebvre, Say Viengchareun, Hussein Kobeissy, Patrick Lechêne, Valerie Nicolas, Amaya Fernández-Celis, Susana Gomez, Sandra Lauton-Santos, Eric Morel, Angelica Rueda, Natalia López-Andrés, Ana M Gomez, Marc Lombes, Jean-Pierre Benitah
<u>Rationale:</u> The mineralocorticoid receptor (MR) antagonists belong to the current therapeutic armamentarium for the management of cardiovascular diseases, but the mechanisms conferring their beneficial effects are poorly understood. Part of the cardiovascular effects of MR are due to the regulation of L-type Cav 1.2 Ca2+ channel expression, which is generated by tissue-specific alternative promoters as a long 'cardiac' (Cav 1.2-LNT) or a short 'vascular' (Cav 1.2-SNT) N-terminal transcripts...
February 21, 2018: Circulation Research
https://www.readbyqxmd.com/read/29462546/role-of-the-renin-angiotensin-system-in-hepatic-fibrosis-and-portal-hypertension
#2
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik
The renin-angiotensin system (RAS) is an important regulator of cirrhosis and portal hypertension. As hepatic fibrosis progresses, levels of the RAS components angiotensin (Ang) II, Ang-(1-7), angiotensin-converting enzyme (ACE), and Ang II type 1 receptor (AT1R) are increased. The primary effector Ang II regulates vasoconstriction, sodium homoeostasis, fibrosis, cell proliferation, and inflammation in various diseases, including liver cirrhosis, through the ACE/Ang II/AT1R axis in the classical RAS. The ACE2/Ang-(1-7)/Mas receptor and ACE2/Ang-(1-9)/AT2R axes make up the alternative RAS and promote vasodilation, antigrowth, proapoptotic, and anti-inflammatory effects; thus, countering the effects of the classical RAS axis to reduce hepatic fibrogenesis and portal hypertension...
February 21, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29460366/ejection-fraction-as-a-statistical-index-of-left-ventricular-systolic-function-the-first-full-allometric-scrutiny-of-its-appropriateness-and-accuracy
#3
Lorenzo Lolli, Alan M Batterham, Greg Atkinson
Left ventricular ejection fraction (EF) is a ratio that is deemed to accurately normalize stroke volume (SV) to end-diastolic volume (EDV). Ratios are now well-recognized for not normalizing the numerator, in this case SV, consistently for the denominator, EDV. We aimed to provide the first allometric-based scrutiny of the conventional assumptions that underpin the EF ratio. We allometrically modelled untransformed SV and EDV measurements from 112 preclinical heart failure patients in the Multi-Ethnic Study of Atherosclerosis (MESA), and 864 chronic heart failure patients in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study...
February 20, 2018: Clinical Physiology and Functional Imaging
https://www.readbyqxmd.com/read/29453922/a-short-review-of-primary-aldosteronism-in-a-question-and-answer-fashion
#4
Frederick-Anthony Farrugia, Nicolaos Zavras, Georgios Martikos, Panagiotis Tzanetis, Anestis Charalampopoulos, Evangelos P Misiakos, Dimitrios Sotiropoulos, Nikolaos Koliakos
OBJECTIVES: The aim of this study was to present up to date information concerning the diagnosis and treatment of primary aldosteronism (PA). PA is the most common cause of endocrine hypertension. It has been reported up to 24% of selective referred hypertensive patients. METHODS: We did a search in Pub-Med and Google Scholar using the terms: PA, hyperaldosteronism, idiopathic adrenal hyperplasia, diagnosis of PA, mineralocorticoid receptor antagonists, adrenalectomy, and surgery...
January 1, 2018: Endocrine Regulations
https://www.readbyqxmd.com/read/29442351/milk-alkali-syndrome-mas-as-a-complication-of-the-treatment-of-hypoparathyroidism
#5
Agata Skwarek, Janusz Pachucki, Tomasz Bednarczuk, Zuzanna Żurecka, Michał Popow
Milk-alkali syndrome (MAS), characterized by renal failure, metabolic alkalosis and hypercalcemia, is a severe and life-threatening complication of the treatment of hypoparathyroidism. The clinical course is often sudden and is not preceded by any prodromal symptoms. Occurrence does not depend on the duration of hypoparathyroidism treatment, although it is closely related to the applied therapy, especially the dose of calcium carbonate and active vitamin D preparations. Drugs influencing the glomerular filtration rate (angiotensin receptor blockers, sartans, aldosterone receptor antagonists, thiazide diuretics), lack of adequate routine control, changing the calcium carbonate supplementation, dehydration, a diet rich in pH-basic foods (i...
February 14, 2018: Endokrynologia Polska
https://www.readbyqxmd.com/read/29440699/vascular-dysfunction-in-obese-diabetic-db-db-mice-involves-the-interplay-between-aldosterone-mineralocorticoid-receptor-and-rho-kinase-signaling
#6
Aurelie Nguyen Dinh Cat, Glaucia E Callera, Malou Friederich-Persson, Ana Sanchez, Maria Gabriela Dulak-Lis, Sofia Tsiropoulou, Augusto C Montezano, Ying He, Ana M Briones, Frederic Jaisser, Rhian M Touyz
Activation of aldosterone/mineralocorticoid receptors (MR) has been implicated in vascular dysfunction of diabetes. Underlying mechanisms are elusive. Therefore, we investigated the role of Rho kinase (ROCK) in aldosterone/MR signaling and vascular dysfunction in a model of diabetes. Diabetic obese mice (db/db) and control counterparts (db/+) were treated with MR antagonist (MRA, potassium canrenoate, 30 mg/kg/day, 4 weeks) or ROCK inhibitor, fasudil (30 mg/kg/day, 3 weeks). Plasma aldosterone was increased in db/db versus db/+...
February 13, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29436482/the-angiotensin-type-2-receptor-in-%C3%A2-human-adrenocortical-zona-glomerulosa-and-in-aldosterone-producing-adenoma-low-expression-and-no-functional-role
#7
Paul Emmanuel Vanderriele, Brasilina Caroccia, Teresa Maria Seccia, Maria Piazza, Livia Lenzini, Francesca Torresan, Maurizio Iacobone, Thomas Unger, Gian Paolo Rossi
The angiotensin II type 2 receptor (AT2R) and the angiotensin-(1-7) receptor (MasR) play a cardiovascular protective role by counter-regulating angiotensin II type 1 receptor (AT1R)-mediated effects, but whether this involves blunting of adrenocortical hormone secretion is unknown. We investigated the presence of AT1R, AT2R and MasR in aldosterone-producing adenoma (APA), a condition featuring hyperaldosteronism, and in APA-adjacent tissue. The effect of C21, an AT2R agonist, on CYP11B1 (cortisol synthase) and CYP11B2 (aldosterone synthase) gene expression in NCI-H295R and HAC15 cell lines, and in APA and APA-adjacent tissue was also assessed using the AT1R antagonist irbesartan to ascertain the specificity of C21 effect...
February 7, 2018: Clinical Science (1979-)
https://www.readbyqxmd.com/read/29429439/clinical-characteristics-and-causes-of-heart-failure-adherence-to-treatment-guidelines-and-mortality-of-patients-with-acute-heart-failure-experience-at-groote-schuur-hospital-cape-town-south-africa
#8
P Z Szymanski, M Badri, B M Mayosi
BACKGROUND: There is limited information on acute heart failure (AHF) and its treatment in sub-Saharan Africa. OBJECTIVE: To describe the clinical characteristics and causes of heart failure (HF), adherence to HF treatment guidelines, and mortality of patients with AHF presenting to Groote Schuur Hospital (GSH), Cape Town, South Africa. METHODS: This sub-study of The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF) was a prospective and observational survey that focused on the enrolment and follow-up of additional patients with AHF presenting to GSH and entered into the existing registry after publication of the primary THESUS-HF article in 2012...
February 1, 2018: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
https://www.readbyqxmd.com/read/29423950/guideline-directed-medical-therapy-and-survival-following-hospitalization-in-patients-with-heart-failure
#9
Richard H Tran, Ahmed Aldemerdash, Patricia Chang, Carla A Sueta, Brystana Kaufman, Josephine Asafu-Adjei, Orly Vardeny, Eliza Daubert, Khalid A Alburikan, Anna M Kucharska-Newton, Sally C Stearns, Jo E Rodgers
BACKGROUND: Modification of guideline-directed medical therapy (GDMT) in hospitalized patients with heart failure (HF) has not been extensively evaluated. METHODS: The community surveillance arm of the Atherosclerosis Risk in Communities Study identified 6959 HF hospitalizations from 2005 to 2011. Predictors of GDMT modification and survival were assessed using multivariable logistic regression and Cox proportional hazards models. RESULTS: For 5091 hospitalizations, patient mean age was 75 years old, 53% were female, 69% were Caucasian, and 81% had acute decompensated HF (ADHF)...
February 9, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29389068/tolvaptan-in-chinese-cirrhotic-patients-with-ascites-a-randomized-placebo-controlled-phase-2-trial
#10
Yongfeng Wang, Jieting Tang, Tao Han, Huiguo Ding, Weijiang Ye, Maorong Wang, Jun Cheng, Yongping Yang, Chengwei Chen, Qing Xie, Qing Mao, Junqi Niu, Zhenghua Wang, Zhong Wei, Yingxuan Chen, Minde Zeng, Yimin Mao
AIM: To evaluate tolvaptan as a novel therapeutic option for Chinese patients with liver cirrhosis-associated ascites in a phase 2 clinical trial. METHODS: This randomized, double-blind, placebo-controlled, multicenter trial was conducted in patients with insufficient responses to combination therapies of an oral loop diuretic and an aldosterone antagonist. Reduction in body weight and abdominal circumference, increase in 24-h cumulative urine volume, and improvement in serum sodium from baseline to end of treatment in the 15 mg and the 30 mg tolvaptan groups were compared to those in the placebo group...
February 1, 2018: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/29348255/hypertension-and-atrial-fibrillation-doubts-and-certainties-from-basic-and-clinical-studies
#11
REVIEW
Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi
Hypertension and atrial fibrillation (AF) are 2 important public health priorities. Their prevalence is increasing worldwide, and the 2 conditions often coexist in the same patient. Hypertension and AF are strikingly related to an excess risk of cardiovascular disease and death. Hypertension ultimately increases the risk of AF, and because of its high prevalence in the population, it accounts for more cases of AF than other risk factors. Among patients with established AF, hypertension is present in about 60% to 80% of individuals...
January 19, 2018: Circulation Research
https://www.readbyqxmd.com/read/29307549/favorable-effects-of-statins-in-the-treatment-of-heart-failure-with-preserved-ejection-fraction-in-patients-without-ischemic-heart-disease
#12
Tetsuro Tsujimoto, Hiroshi Kajio
BACKGROUND: The effects of statins in patients with heart failure with preserved ejection fraction (HFpEF) remain unclear. This study aimed to assess whether statin therapy is associated with a decreased risk of mortality in patients with HFpEF. METHODS: We used data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. The primary outcome was all-cause mortality. We analyzed hazard ratios (HRs) for outcomes with 95% confidence intervals (95% CIs) in patients taking statins compared with those not taking statins using multivariable Cox proportional hazard models...
January 4, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29305104/heart-failure-with-mid-range-ejection-fraction-in-patients-admitted-to-internal-medicine-departments-findings-from-the-rica-registry
#13
María Esther Guisado-Espartero, Prado Salamanca-Bautista, Óscar Aramburu-Bodas, Alicia Conde-Martel, José Luis Arias-Jiménez, Pau Llàcer-Iborra, Melitón Francisco Dávila-Ramos, Yolanda Cabanes-Hernández, Luis Manzano, Manuel Montero-Pérez-Barquero
AIM: To improve the knowledge on characteristics, treatment and prognosis in patients with heart failure (HF) and mid-range ejection fraction discharged after an acute HF episode. METHODS: We prospectively included and followed 2753 patients admitted with HF to Internal Medicine units. Patients were classified according to ejection fraction (EF) into three strata: reduced, EF <40% (HFrEF); mid-range EF 40-49% (HFmrEF); and preserved EF ≥50% (HFpEF). Clinical, echocardiographic, laboratory data and treatment at discharge were recorded and the groups were compared...
January 2, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29300219/the-effect-of-a-non-peptide-angiotensin-ii-type-2-receptor-agonist-compound-21-on-aortic-aneurysm-growth-in-a-mouse-model-of-marfan-syndrome
#14
Peter Verbrugghe, Jelle Verhoeven, Marnick Clijsters, Dominique Vervoort, Jarne Schepens, Bart Meuris, Paul Herijgers
IntroductionAvailable evidence suggests that the renin-angiotensin-aldosterone (RAA) system is a good target for medical intervention on aortic root dilatation in Marfan syndrome (MFS). The effect of Compound 21 (C21), a non-peptide angiotensin II type 2 receptor (AT2R) agonist on aneurysm progression is was tested.MethodsMice with a mutation in fibrillin-1 (Fbn1C1039G/+) and wild-type (WT) mice were treated with vehicle, losartan, C21, enalapril or a combination. Blood pressure, aortic root diameter, and histological slides were evaluated...
January 3, 2018: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/29277469/the-seisicat-study-a-pilot-study-assessing-efficacy-and-safety-of-spironolactone-in-cats-with-congestive-heart-failure-secondary-to-cardiomyopathy
#15
Rachel James, Emilie Guillot, Catherine Garelli-Paar, Jacqueline Huxley, Vanessa Grassi, Malcolm Cobb
INTRODUCTION: The pathophysiology of heart failure involves activation of several neurohormonal systems including the renin-angiotensin-aldosterone system. The mineralocorticoid receptor antagonist spironolactone has been shown to be beneficial in humans and dogs with heart failure. The objective of this pilot study was to investigate the efficacy and safety of spironolactone in cats with heart failure secondary to cardiomyopathy already treated with furosemide and an angiotensin-converting enzyme inhibitor...
December 22, 2017: Journal of Veterinary Cardiology: the Official Journal of the European Society of Veterinary Cardiology
https://www.readbyqxmd.com/read/29276242/underutilization-of-aldosterone-antagonists-in-heart-failure
#16
Shanise J Patterson, Anne B Reaves, Elizabeth A Tolley, Dagny Ulrich, Christopher Hilty, Catherine J Clarke, Timothy H Self
Background: Treatment with an aldosterone antagonist (AA) has been shown in multiple trials to reduce heart failure (HF)-related morbidity, mortality, and hospital readmission. American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) treatment guidelines recommend the use of an AA in all HF patients with an ejection fraction ≤35% and no known contraindication. Several studies have documented underuse of AA. Objectives: To determine the proportion of patients who received AA therapy consistent with the ACCF/AHA guidelines...
November 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29274772/evidence-for-the-use-of-mineralocorticoid-receptor-antagonists-in-the-treatment-of-coronary-artery-disease-and-post-angioplasty-restenosis
#17
REVIEW
Jochen Dutzmann, Johann Bauersachs, Daniel G Sedding
Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone have an established role in the treatment of heart failure. However, many experimental and clinical studies have shown that aldosterone also plays a pivotal role in a variety of other pathophysiological conditions within the cardiovascular system. Aldosterone has been suggested to promote inflammation, endothelial dysfunction and smooth muscle cell hyperplasia during the development of atherosclerosis, thereby promoting the development of coronary artery disease (CAD)...
December 21, 2017: Vascular Pharmacology
https://www.readbyqxmd.com/read/29251761/single-pill-combinations-spcs-and-treatment-of-arterial-hypertension-in-poland-expert-consensus-statement-of-the-polish-society-of-hypertension-and-polish-cardiac-society-working-group-on-cardiovascular-pharmacotherapy
#18
Andrzej Tykarski, Krystyna Widecka, Krzysztof Narkiewicz, Beata Wożakowska-Kapłon, Zbigniew Gaciong, Stefan Grajek, Tomasz Grodzicki, Andrzej Januszewicz, Jacek Wolf, Aleksander Prejbisz, Katarzyna Kostka-Jeziorny, Krzysztof J Filipiak
The reasons for the publication of current expert consensus statement after 4 years from the previous one are: the growing number of evidence on the benefits of the use of single-pill combinations (SPCs) in hypertension (also with concomitant dyslipidaemia), the extension of indications for their use in the hypertension management algorithm and the emergence in recent years after the publication of Polish Society of Hypertension experts' position statement in 2013 of new types of SPCs available to doctors in Poland, including triple-drug combinations of antihypertensives and the so-called "hybrids" SPCs containing not only antihypertensive drugs but also statins...
2017: Kardiologia Polska
https://www.readbyqxmd.com/read/29233053/evaluation-of-a-pharmacist-driven-aldosterone-antagonist-stewardship-program-in-patients-with-heart-failure
#19
Eric R Sparks, Janna C Beavers
OBJECTIVE: To evaluate the impact of a pharmacist-driven initiative to optimize aldosterone antagonist use in patients with heart failure with reduced ejection fraction (HFrEF) at a large community hospital. METHODS: This single-center, retrospective cohort study compared patients with heart failure before and after the implementation of the initiative. Data for pre- and postinitiative patients were retrospectively collected to assess patient characteristics and aldosterone antagonist use...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/29227582/role-of-the-sodium-hydrogen-exchanger-in-mediating-the-renal-effects-of-drugs-commonly-used-in-the-treatment-of-type-2-diabetes
#20
REVIEW
Milton Packer
Diabetes is characterized by an increased activity of the sodium-hydrogen exchanger (NHE) in the glomerulus and renal tubules, which contributes importantly to the development of nephropathy. Despite the established role played by the exchanger in experimental studies, it has not been specifically targeted by those seeking to develop novel pharmacological treatments for diabetes. This review demonstrates that many existing drugs that are commonly prescribed to patients with diabetes act on the NHE1 and NHE3 isoforms in the kidney...
December 11, 2017: Diabetes, Obesity & Metabolism
keyword
keyword
10485
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"